Alfuzosin
- TRADE NAMES: Uroxatral (Concordia); Xatral (Sanofi-Aventis)
- INDICATIONS: Benign prostatic hyperplasia
- CLASS: Adrenergic alpha-receptor antagonist
- HALF-LIFE: 10 hours
ACE inhibitors, Adrenergic neurone blockers, Alcohol, Aldesleukin, Alprostadil, Amitriptyline, Angiotensin II receptor antagonists, Antipsychotics, Anxiolytics and hypnotics, Arsenic, Atazanavir, Atenolol, Baclofen, Beta blockers, Boceprevir, Calcium channel blockers, Cimetidine, Citalopram, Clonidine, Conivaptan, Corticosteroids, CYP3A4 inducers or inhibitors, Darunavir, Dasatinib, Deferasirox, Degarelix, Delavirdine, Diazoxide, Diltiazem, Diuretics, Dolasetron, Estrogens, Food, General anesthetics, Hydralazine, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Levodopa, Levofloxacin, Lopinavir, MAO inhibitors, Methyldopa, Minoxidil, Moxifloxacin, Moxisylyte, Moxonidine, Nelfinavir, Nitrates, Nitroprusside, NSAIDs, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Pazopanib, Phosphodiesterase 5 inhibitors, Protease inhibitors, QT prolonging agents, Ritonavir, Sildenafil, St John's Wort, Tadalafil, Telaprevir, Telavancin, Telithromycin, Tipranavir, Tizanidine, Vardenafil, Voriconazole, Vorinostat, Ziprasidone
PREGNANCY CATEGORY: B
Please login to see the rest of this drug profile
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
